This represents an entirely different mechanistic approach - oral insulin delivery - which could reshape the T2D treatment algorithm if approvals and commercialization succeed
Cracking the BAFF code
This treatment supports energy levels, enhances overall metabolic function, and promotes better circulation and nerve health for those living with these conditions
Sources Voy clinical nutrition team
To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Experts to discuss AIDING results for automated insulin delivery in the hospital Francisco Pasquel, MD, MPH, and other experts will share findings from this study evaluating automated insulin delivery initiated in the hospital compared with daily injections in people with type 1 or type 2 diabetes
